Other potential applications of this pathological strategy in oncology concern the IHC screening of several other genomic alterations including ALK1 and ROS1 fusions and BRAF-(V600E) mutations which may be drivers of various neoplastic forms, regardless of the tumor type, and could be treated in a near future with drugs already available for treatment of lung adenocarcinomas (ALK1 and ROS1) and melanoma and lung carcinoma (BRAF) patients [2, 3, 27]. This evidence concerns the gene BRAF and melanoma.